TTX-030 + mFOLFOX6

TTX-030 + mFOLFOX6 is a combination regimen composed of TTX-030, a monoclonal antibody targeting CD39, together with mFOLFOX6, a modified standard chemotherapy regimen. - **TTX-030** is a monoclonal antibody designed to inhibit CD39 (ectonucleoside triphosphate diphosphohydrolase-1), thereby modulating the tumor microenvironment and promoting anti-tumor immune responses. TTX-030 is under development by Trishula Therapeutics (a Gritstone subsidiary), with development collaborations reported with AbbVie. - **mFOLFOX6** is a chemotherapy regimen used in colorectal and other gastrointestinal cancers containing 5-fluorouracil (5-FU), leucovorin (folinic acid), and oxaliplatin, widely used as standard of care in colorectal cancer regimens[1][2][4][5][6]. The mFOLFOX6 regimen is a "modified" version of FOLFOX6, with specific dosing schedules to minimize toxicity while maintaining efficacy. This combination is being studied in clinical trials, particularly for advanced gastrointestinal malignancies, where TTX-030 is hypothesized to promote immune-mediated tumor killing when added to standard cytotoxic chemotherapy.

Other names

TTX-030 plus mFOLFOX6TTX030 plus mFOLFOX6TTX 030 plus mFOLFOX6TTX-030 + modified FOLFOX6TTX-030 combined with mFOLFOX6TTX030 combined with mFOLFOX6TTX 030 combined with mFOLFOX6